Shares of Furiex Pharmaceuticals (UNKNOWN:FURX.DX) exploded today, up 145% as the company released data that its drug treating a form of IBS that results in diarrhea passed its phase 3 trials, soundly beating a placebo at the higher dosing.
In this video, Motley Fool health-care analyst David Williamson discusses whether or not he thinks the drug will be approved and what the potential market size could be, and looks at just how high this stock could go.
David Williamson owns shares of AbbVie. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.